NUTEX HEALTH INC (NUTX) Stock Fundamental Analysis
NASDAQ:NUTX - Nasdaq - US67079U3068 - Common Stock - Currency: USD
Overall NUTX gets a fundamental rating of 6 out of 10. We evaluated NUTX against 102 industry peers in the Health Care Providers & Services industry. NUTX has an excellent financial health rating, but there are some minor concerns on its profitability. NUTX is not priced too expensively while it is growing strongly. Keep and eye on this one! This makes NUTX very considerable for growth investing!
1. Profitability
1.1 Basic Checks
NUTX had positive earnings in the past year.
NUTX had a positive operating cash flow in the past year.
In the past 5 years NUTX reported 4 times negative net income.
In multiple years NUTX reported negative operating cash flow during the last 5 years.
1.2 Ratios
NUTX has a better Return On Assets (8.82%) than 93.14% of its industry peers.
Looking at the Return On Equity, with a value of 34.08%, NUTX belongs to the top of the industry, outperforming 96.08% of the companies in the same industry.
NUTX has a better Return On Invested Capital (30.54%) than 99.02% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 8.82% | ||
| ROE | 34.08% | ||
| ROIC | 30.54% |
ROA(3y)-33.97%
ROA(5y)-688.28%
ROE(3y)-160.63%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin of NUTX (10.76%) is better than 96.08% of its industry peers.
The Operating Margin of NUTX (33.39%) is better than 98.04% of its industry peers.
With a decent Gross Margin value of 48.77%, NUTX is doing good in the industry, outperforming 76.47% of the companies in the same industry.
NUTX's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 33.39% | ||
| PM (TTM) | 10.76% | ||
| GM | 48.77% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y22.83%
GM growth 5Y0.83%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so NUTX is creating value.
Compared to 1 year ago, NUTX has less shares outstanding
The number of shares outstanding for NUTX has been increased compared to 5 years ago.
The debt/assets ratio for NUTX has been reduced compared to a year ago.
2.2 Solvency
An Altman-Z score of 2.18 indicates that NUTX is not a great score, but indicates only limited risk for bankruptcy at the moment.
With a Altman-Z score value of 2.18, NUTX perfoms like the industry average, outperforming 50.98% of the companies in the same industry.
NUTX has a debt to FCF ratio of 4.45. This is a neutral value as NUTX would need 4.45 years to pay back of all of its debts.
The Debt to FCF ratio of NUTX (4.45) is better than 69.61% of its industry peers.
NUTX has a Debt/Equity ratio of 1.46. This is a high value indicating a heavy dependency on external financing.
The Debt to Equity ratio of NUTX (1.46) is worse than 68.63% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.46 | ||
| Debt/FCF | 4.45 | ||
| Altman-Z | 2.18 |
ROIC/WACC4.39
WACC6.96%
2.3 Liquidity
A Current Ratio of 2.27 indicates that NUTX has no problem at all paying its short term obligations.
NUTX has a better Current ratio (2.27) than 80.39% of its industry peers.
A Quick Ratio of 2.26 indicates that NUTX has no problem at all paying its short term obligations.
NUTX has a Quick ratio of 2.26. This is amongst the best in the industry. NUTX outperforms 81.37% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.27 | ||
| Quick Ratio | 2.26 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 430.28% over the past year.
The Revenue has grown by 141.25% in the past year. This is a very strong growth!
The Revenue has been growing by 222.96% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)430.28%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%526.67%
Revenue 1Y (TTM)141.25%
Revenue growth 3Y194.48%
Revenue growth 5Y222.96%
Sales Q2Q%213.98%
3.2 Future
NUTX is expected to show a very negative growth in Earnings Per Share. In the coming years, the EPS will decrease by -27.81% yearly.
NUTX is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 28.17% yearly.
EPS Next Y-36.62%
EPS Next 2Y-27.81%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year53.08%
Revenue Next 2Y28.17%
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
NUTX is valuated reasonably with a Price/Earnings ratio of 10.26.
Compared to the rest of the industry, the Price/Earnings ratio of NUTX indicates a rather cheap valuation: NUTX is cheaper than 92.16% of the companies listed in the same industry.
NUTX is valuated cheaply when we compare the Price/Earnings ratio to 26.52, which is the current average of the S&P500 Index.
With a Price/Forward Earnings ratio of 26.82, NUTX can be considered very expensive at the moment.
NUTX's Price/Forward Earnings ratio is in line with the industry average.
NUTX's Price/Forward Earnings ratio indicates a valuation a bit more expensive than the S&P500 average which is at 22.25.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 10.26 | ||
| Fwd PE | 26.82 |
4.2 Price Multiples
NUTX's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. NUTX is cheaper than 96.08% of the companies in the same industry.
NUTX's Price/Free Cash Flow ratio is rather cheap when compared to the industry. NUTX is cheaper than 87.25% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 9.79 | ||
| EV/EBITDA | 3.96 |
4.3 Compensation for Growth
NUTX has a very decent profitability rating, which may justify a higher PE ratio.
NUTX's earnings are expected to decrease with -27.81% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-27.81%
EPS Next 3YN/A
5. Dividend
5.1 Amount
No dividends for NUTX!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
122.02
-1.38 (-1.12%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)
Earnings (Next)
Inst Owners16.4%
Inst Owner Change-80.67%
Ins Owners2.22%
Ins Owner Change0%
Market Cap679.65M
Analysts82.22
Price Target197.54 (61.89%)
Short Float %6.22%
Short Ratio1.51
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly Dividend0.25
Dividend Growth(5Y)N/A
DP19.83%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)4474.63%
Min EPS beat(2)9.6%
Max EPS beat(2)8939.67%
EPS beat(4)3
Avg EPS beat(4)2105.75%
Min EPS beat(4)-602.61%
Max EPS beat(4)8939.67%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)143.87%
Min Revenue beat(2)76.42%
Max Revenue beat(2)211.33%
Revenue beat(4)4
Avg Revenue beat(4)75.65%
Min Revenue beat(4)5.5%
Max Revenue beat(4)211.33%
Revenue beat(8)5
Avg Revenue beat(8)36.33%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)41.67%
PT rev (3m)60.21%
EPS NQ rev (1m)136.68%
EPS NQ rev (3m)505.3%
EPS NY rev (1m)33.4%
EPS NY rev (3m)336.33%
Revenue NQ rev (1m)84.37%
Revenue NQ rev (3m)120.71%
Revenue NY rev (1m)13.16%
Revenue NY rev (3m)33.81%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 10.26 | ||
| Fwd PE | 26.82 | ||
| P/S | 1.09 | ||
| P/FCF | 9.79 | ||
| P/OCF | 9.56 | ||
| P/B | 3.45 | ||
| P/tB | 4.05 | ||
| EV/EBITDA | 3.96 |
EPS(TTM)11.89
EY9.74%
EPS(NY)4.55
Fwd EY3.73%
FCF(TTM)12.47
FCFY10.22%
OCF(TTM)12.76
OCFY10.46%
SpS112.08
BVpS35.39
TBVpS30.16
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 8.82% | ||
| ROE | 34.08% | ||
| ROCE | 35.61% | ||
| ROIC | 30.54% | ||
| ROICexc | 35.64% | ||
| ROICexgc | 37.81% | ||
| OM | 33.39% | ||
| PM (TTM) | 10.76% | ||
| GM | 48.77% | ||
| FCFM | 11.12% |
ROA(3y)-33.97%
ROA(5y)-688.28%
ROE(3y)-160.63%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y22.83%
GM growth 5Y0.83%
F-Score8
Asset Turnover0.82
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.46 | ||
| Debt/FCF | 4.45 | ||
| Debt/EBITDA | 1.26 | ||
| Cap/Depr | 8.22% | ||
| Cap/Sales | 0.26% | ||
| Interest Coverage | 59.03 | ||
| Cash Conversion | 31.12% | ||
| Profit Quality | 103.36% | ||
| Current Ratio | 2.27 | ||
| Quick Ratio | 2.26 | ||
| Altman-Z | 2.18 |
F-Score8
WACC6.96%
ROIC/WACC4.39
Cap/Depr(3y)59.19%
Cap/Depr(5y)N/A
Cap/Sales(3y)3.66%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)430.28%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%526.67%
EPS Next Y-36.62%
EPS Next 2Y-27.81%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)141.25%
Revenue growth 3Y194.48%
Revenue growth 5Y222.96%
Sales Q2Q%213.98%
Revenue Next Year53.08%
Revenue Next 2Y28.17%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y4652.96%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year1064.59%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y98.21%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y31.51%
OCF growth 3YN/A
OCF growth 5YN/A